Approximately 15,642 Shares Of Cidara Therapeutics Inc. (CDTX) Were Sold By This Insider.


Cidara Therapeutics Inc. (NASDAQ:CDTX) finished Friday with an addition of $0.01 to close at $0.76, an upside of 0.19 percent. An average of 507,520 shares of common stock have been traded in the last five days. There was a gain of $0.1316 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 408,340 shares traded, while the 50-day average volume stands at 323,176.

CDTX stock has increased by 18.15% in the last month. The company shares reached their 1-month lowest point of $0.4601 on 12/08/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.40 and a high of $1.41 in 52 weeks. It has reached a new high 1 time so far this year and lost -40.45% or -$0.5137 in price. In spite of this, the price is down -46.36% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

CDTX stock investors should be aware that Cidara Therapeutics Inc. (CDTX) stock had its last reported insider trading activity 103 days ago on Sep 19. In this transaction, the insider spent $12,035. Chief Medical Officer, Sandison Taylor, disposed of 18,478 shares at a price of $0.68 on Sep 12. The insider now owns more than $12,656 worth of shares. Prior to that, CHIEF SCIENTIFIC OFFICER Tari Leslie went on to Sale 18,159 shares at $0.68 each on Sep 12. An amount of $12,437 was transacted.

Valuation Metrics

Cidara Therapeutics Inc. (CDTX) stock’s beta is 1.39. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.81, the price-to-book (PB) ratio at 5.82.

Financial Health

The quick ratio of Cidara Therapeutics Inc. for the three months ended September 29 was 1.90, and the current ratio was 1.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $91.83 million compared to revenue of $49.57 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cidara Therapeutics Inc.’s return on assets was -58.60%.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $11.9 million in the quarter, while revenues of -$13.12 million were grew 251.93%. The analyst consensus anticipated Cidara Therapeutics Inc.’s latest quarter earnings to come in at $0.18 per share, but it turned out to be $0.17, a -5.60% surprise. For the quarter, EBITDA amounted to $17.0 million. Shareholders own equity worth $71.62 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Cidara Therapeutics Inc. (CDTX) price momentum. RSI 9-day as of the close on 30 December was 72.84%, suggesting the stock is Overbought, with historical volatility in this time frame at 124.83%.

As of today, CDTX’s price is $0.6966 +21.07% or $0.1316 from its 5-day moving average. CDTX is currently trading +16.30% higher than its 20-day SMA and +20.99% higher than its 100-day SMA. However, the stock’s current price level is +33.39% above the SMA50 and +6.96% above the SMA200.

The stochastic %K and %D were 84.32% and 83.38%, respectively, and the average true range (ATR) was 0.0852. With the 14-day stochastic at 89.66% and the average true range at 0.0770, the RSI (14) stands at 66.95%. The stock has reached 0.0932 on the 9-day MACD Oscillator while the 14-day reading was at 0.1296.

Analyst Ratings

The consensus rating for Cidara Therapeutics Inc. (CDTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CDTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.

What is CDTX’s price target for the next 12 months?

Analysts predict a range of price targets between $5.00 and $6.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Cidara Therapeutics Inc. (CDTX) stock is $5.67.


Please enter your comment!
Please enter your name here